Comparison of the immunogenicity of five COVID-19 vaccines in Sri Lanka
To determine the antibody responses elicited by different vaccines against SARS-CoV-2, we compared antibody responses in individuals 3 months post-vaccination in those who had received different vaccines in Sri Lanka. Abs to the receptor binding domain (RBD) of the ancestral (wild type) virus (WT) a...
| Автори: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Формат: | Journal article |
| Мова: | English |
| Опубліковано: |
Wiley
2022
|
| _version_ | 1826310907154661376 |
|---|---|
| author | Jeewandara, C Aberathna, IS Danasekara, S Gomes, L Fernando, S Guruge, D Ranasinghe, T Gunasekera, B Kamaladasa, A Kuruppu, H Somathilake, G Jayamali, J Jayathilaka, D Wijayatilake, HDK Pushpakumara, PD Harvie, M Nimasha, T de Silva, SDG Wijayamuni, R Schimanski, L Rijal, P Tan, J Townsend, A Ogg, GS Malavige, GN |
| author_facet | Jeewandara, C Aberathna, IS Danasekara, S Gomes, L Fernando, S Guruge, D Ranasinghe, T Gunasekera, B Kamaladasa, A Kuruppu, H Somathilake, G Jayamali, J Jayathilaka, D Wijayatilake, HDK Pushpakumara, PD Harvie, M Nimasha, T de Silva, SDG Wijayamuni, R Schimanski, L Rijal, P Tan, J Townsend, A Ogg, GS Malavige, GN |
| author_sort | Jeewandara, C |
| collection | OXFORD |
| description | To determine the antibody responses elicited by different vaccines against SARS-CoV-2, we compared antibody responses in individuals 3 months post-vaccination in those who had received different vaccines in Sri Lanka. Abs to the receptor binding domain (RBD) of the ancestral (wild type) virus (WT) as well as to variants of concern (VoCs), and ACE2 blocking Abs, were assessed in individuals vaccinated with Moderna (n = 225), Sputnik V (n = 128) or Sputnik light (n = 184) and the results were compared with previously reported data on Sinopharm and AZD1222 vaccinees. A total of 99.5% of Moderna, >94% of AZD1222 or Sputnik V and >70% of Sputnik light, >60% of Sinopharm vaccine recipients, had a positive response to ACE2 blocking antibodies. The ACE2 blocking antibody levels were highest to lowest was Moderna > Sputnik V/AZD1222 (had equal levels) > Sputnik light > Sinopharm. All Moderna recipients had antibodies to the RBD of WT, alpha and beta, while positivity rates for delta variant was 80%. The positivity rates for Sputnik V vaccinees for the WT and VoCs were higher than for AZD1222 vaccinees while those who received Sinopharm had the lowest positivity rates (<16.7%). The total antibodies to the RBD were highest for the Sputnik V and AZD1222 vaccinees. The Moderna vaccine elicited the highest ACE2 blocking antibody levels followed by Sputnik V/AZD1222, while those who received Sinopharm had the lowest levels. These findings highlight the need for further studies to understand the effects on clinical outcomes. |
| first_indexed | 2024-03-07T08:00:24Z |
| format | Journal article |
| id | oxford-uuid:672bcb8c-c50b-4963-84c0-97f5d4072196 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T08:00:24Z |
| publishDate | 2022 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:672bcb8c-c50b-4963-84c0-97f5d40721962023-09-26T15:20:29ZComparison of the immunogenicity of five COVID-19 vaccines in Sri LankaJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:672bcb8c-c50b-4963-84c0-97f5d4072196EnglishSymplectic ElementsWiley2022Jeewandara, CAberathna, ISDanasekara, SGomes, LFernando, SGuruge, DRanasinghe, TGunasekera, BKamaladasa, AKuruppu, HSomathilake, GJayamali, JJayathilaka, DWijayatilake, HDKPushpakumara, PDHarvie, MNimasha, Tde Silva, SDGWijayamuni, RSchimanski, LRijal, PTan, JTownsend, AOgg, GSMalavige, GNTo determine the antibody responses elicited by different vaccines against SARS-CoV-2, we compared antibody responses in individuals 3 months post-vaccination in those who had received different vaccines in Sri Lanka. Abs to the receptor binding domain (RBD) of the ancestral (wild type) virus (WT) as well as to variants of concern (VoCs), and ACE2 blocking Abs, were assessed in individuals vaccinated with Moderna (n = 225), Sputnik V (n = 128) or Sputnik light (n = 184) and the results were compared with previously reported data on Sinopharm and AZD1222 vaccinees. A total of 99.5% of Moderna, >94% of AZD1222 or Sputnik V and >70% of Sputnik light, >60% of Sinopharm vaccine recipients, had a positive response to ACE2 blocking antibodies. The ACE2 blocking antibody levels were highest to lowest was Moderna > Sputnik V/AZD1222 (had equal levels) > Sputnik light > Sinopharm. All Moderna recipients had antibodies to the RBD of WT, alpha and beta, while positivity rates for delta variant was 80%. The positivity rates for Sputnik V vaccinees for the WT and VoCs were higher than for AZD1222 vaccinees while those who received Sinopharm had the lowest positivity rates (<16.7%). The total antibodies to the RBD were highest for the Sputnik V and AZD1222 vaccinees. The Moderna vaccine elicited the highest ACE2 blocking antibody levels followed by Sputnik V/AZD1222, while those who received Sinopharm had the lowest levels. These findings highlight the need for further studies to understand the effects on clinical outcomes. |
| spellingShingle | Jeewandara, C Aberathna, IS Danasekara, S Gomes, L Fernando, S Guruge, D Ranasinghe, T Gunasekera, B Kamaladasa, A Kuruppu, H Somathilake, G Jayamali, J Jayathilaka, D Wijayatilake, HDK Pushpakumara, PD Harvie, M Nimasha, T de Silva, SDG Wijayamuni, R Schimanski, L Rijal, P Tan, J Townsend, A Ogg, GS Malavige, GN Comparison of the immunogenicity of five COVID-19 vaccines in Sri Lanka |
| title | Comparison of the immunogenicity of five COVID-19 vaccines in Sri Lanka |
| title_full | Comparison of the immunogenicity of five COVID-19 vaccines in Sri Lanka |
| title_fullStr | Comparison of the immunogenicity of five COVID-19 vaccines in Sri Lanka |
| title_full_unstemmed | Comparison of the immunogenicity of five COVID-19 vaccines in Sri Lanka |
| title_short | Comparison of the immunogenicity of five COVID-19 vaccines in Sri Lanka |
| title_sort | comparison of the immunogenicity of five covid 19 vaccines in sri lanka |
| work_keys_str_mv | AT jeewandarac comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT aberathnais comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT danasekaras comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT gomesl comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT fernandos comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT guruged comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT ranasinghet comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT gunasekerab comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT kamaladasaa comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT kuruppuh comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT somathilakeg comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT jayamalij comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT jayathilakad comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT wijayatilakehdk comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT pushpakumarapd comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT harviem comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT nimashat comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT desilvasdg comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT wijayamunir comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT schimanskil comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT rijalp comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT tanj comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT townsenda comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT ogggs comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka AT malavigegn comparisonoftheimmunogenicityoffivecovid19vaccinesinsrilanka |